Factors influencing the efficacy of recombinant tissue plasminogen activator: Implications for ischemic stroke treatment
PLOS ONE · 2024
DOI: 10.1371/journal.pone.0302269 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Jan Víteček und 7 weiteren Autor:innen. Beteiligte Einrichtung: International Clinical Research Center, St. Anne's University Hospital Brno, Brno, Czech Republic. Hauptthemen laut MEDLINE: Tissue Plasminogen Activator, Ischemic Stroke, Recombinant Proteins, Heparin. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Regional Development Fund, Masarykova Univerzita, Brno City Municipality.
Themen: Schlaganfall
Abstract (Originalsprache)
Intravenous thrombolysis with a recombinant tissue plasminogen activator (rt-PA) is the first-line treatment of acute ischemic stroke. However, successful recanalization is relatively low and the underlying processes are not completely understood. The goal was to provide insights into clinically important factors potentially limiting rt-PA efficacy such as clot size, rt-PA concentration, clot age and also rt-PA in combination with heparin anticoagulant. We established a static in vitro thrombolytic model based on red blood cell (RBC) dominant clots prepared using spontaneous clotting from the blood of healthy donors. Thrombolysis was determined by clot mass loss and by RBC release. The rt-PA became increasingly less efficient for clots larger than 50 μl at a clinically relevant concentration of 1.3 mg/l. A tenfold decrease or increase in concentration induced only a 2-fold decrease or increase in clot degradation. Clot age did not affect rt-PA-induced thrombolysis but 2-hours-old clots were degraded more readily due to higher activity of spontaneous thrombolysis, as compared to 5-hours-old clots. Finally, heparin (50 and 100 IU/ml) did not influence the rt-PA-induced thrombolysis. Our study provided in vitro evidence for a clot size threshold: clots larger than 50 μl are hard to degrade by rt-PA. Increasing rt-PA concentration provided limited thrombolytic efficacy improvement, whereas heparin addition had no effect. However, the higher susceptibility of younger clots to thrombolysis may prompt a shortened time from the onset of stroke to rt-PA treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- International Clinical Research Center, St. Anne's University Hospital Brno, Brno, Czech Republic.
- Biophysics of Immune System, Institute of Biophysics of the Czech Academy of Sciences, Brno, Czech Republic.
- Department of Anatomy, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
- Department of Biochemistry, Faculty of Science, Masaryk University, Brno, Czech Republic.
- Department of Histology and Embryology, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
ORCID-Profile: Jan Víteček, Sumeet Gulati, Michaela Capandová
Förderung
- European Regional Development Fund
- Masarykova Univerzita
- Brno City Municipality
Zitieren
APA
Víteček, J., Vítečková Wünschová, A., Thalerová, S., Gulati, S., Kubala, L., Capandová, M., Hampl, A., & Robert Mikulík (2024). Factors influencing the efficacy of recombinant tissue plasminogen activator: Implications for ischemic stroke treatment. PLOS ONE. https://doi.org/10.1371/journal.pone.0302269
Vancouver
Víteček J, Vítečková Wünschová A, Thalerová S, Gulati S, Kubala L, Capandová M, et al. Factors influencing the efficacy of recombinant tissue plasminogen activator: Implications for ischemic stroke treatment. PLOS ONE. 2024. doi:10.1371/journal.pone.0302269
BibTeX
@article{Vteek2024,
author = {Víteček, Jan and Vítečková Wünschová, Andrea and Thalerová, Sandra and Gulati, Sumeet and Kubala, Lukáš and Capandová, Michaela and Hampl, Aleš and Robert Mikulík},
title = {Factors influencing the efficacy of recombinant tissue plasminogen activator: Implications for ischemic stroke treatment},
journal = {PLOS ONE},
year = {2024},
doi = {10.1371/journal.pone.0302269}
}
EUVIMED